Imipenem/Cilastatin Kabi

Imipenem, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It is combined with cilastatin, a renal dehydropeptidase inhibitor, to treat serious bacterial infections in hospitalized patients. GNH USA supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/Cilastatin Kabi is employed for severe bacterial infections that require broad‑spectrum intravenous therapy. - Complicated intra‑abdominal infections: achieves bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens in hospitalized patients. - Skin and soft tissue infections: resolves deep or necrotizing infections caused by Gram‑negative and Gram‑positive bacteria. - Febrile neutropenia: provides empiric coverage against high‑risk pathogens in neutropenic fever. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Injection site pain: discomfort at the infusion site. - Elevated liver enzymes: transient increase in transaminases. - Headache: mild, often resolves after therapy.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders or high doses. - Anaphylaxis: severe, potentially life‑threatening hypersensitivity reaction. - Clostridioides difficile‑associated diarrhea: may result in colitis. - Severe hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal toxicity: acute kidney injury in susceptible individuals. - Neutropenia: marked reduction in white blood cell count.

Use of Imipenem/Cilastatin Kabi requires careful clinical assessment and monitoring. - Renal function: adjust dosing in patients with impaired renal clearance. - Seizure risk: monitor patients with a history of seizures or CNS disorders. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or cilastatin. - Pregnancy: prescribe only when the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications for possible interactions that may affect efficacy or safety. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin Kabi can interact with several medicines, influencing safety or effectiveness.

Major Interactions (Avoid): - Valproic acid: may increase the risk of seizures. - CNS stimulants (e.g., methylphenidate): may lower seizure threshold. - Nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal injury.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance and affect drug levels. - Probenecid: can increase plasma concentrations of imipenem. - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction.